FDA panel backs down-classifying HIV drug resistance tests
This article was originally published in Clinica
A US FDA advisory committee has recommended that HIV genotype drug resistance assays be moved from Class III (high-risk) devices to Class II (medium-risk) devices. Lowering the classification would speed up approval of these products at a time when the ability of the virus to mutate is causing once-successful drugs to fail.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.